NICE overhauls CKD guideline

NICE has updated its clinical guideline on the diagnosis and treatment of chronic kidney disease (CKD) in adults.

CKD is common, frequently unrecognised and often exists together with other conditions such as cardiovascular disease and diabetes. | SCIENCE PHOTO LIBRARY
CKD is common, frequently unrecognised and often exists together with other conditions such as cardiovascular disease and diabetes. | SCIENCE PHOTO LIBRARY

The recommendations for the diagnosis, classification and management of CKD have changed significantly in the new guidance (CG182).

The grades of CKD previously specified have been replaced with two separate alphanumerical identifiers for renal function (GFR category G1-G5 with the same thresholds as the CKD stages 1-5 used previously) and level of albuminuria (ACR category A1-A3) derived from the Kidney Disease: Improving Global Outcomes Work Group.

Prescribers should now classify CKD using a combination of these GFR and ACR categories and should be aware that increased ACR or decreased GFR are both associated with an increased risk of adverse outcomes, and the combination of increased ACR and decreased GFR multiplies the risk of adverse outcomes.

Patients with CKD who require treatment with an antihypertensive can now be offered any low-cost renin-angiotensin system antagonist, including a first-line ACE inhibitor (as previously recommended), an angiotensin II receptor antagonist or the direct renin inhibitor aliskiren.

The guideline also provides advice on patient self-management, recommending that patients are provided with information about exercise, diet and lowering their blood pressure.

The new guidance "will enable doctors to make the correct diagnosis of CKD, and make sure that the right people get the right treatment for their condition," according to Professor Mark Baker, Director of the Centre for Clinical Practice at NICE.

A quick-reference MIMS summary of the new guideline will appear in MIMS in due course.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...